Callan Family Office LLC Boosts Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Callan Family Office LLC increased its stake in Edwards Lifesciences Corporation by 316.6% during the 2nd quarter, holding 36,199 shares worth approximately $2.83 million.
• Edwards Lifesciences Corporation reported $1.53 billion in revenue for the last quarter, exceeding analyst expectations, with an earnings per share (EPS) of $0.67.
• Several analysts have set positive price targets for Edwards Lifesciences, with estimates increasing to as high as $95.00, reflecting a consensus rating of "Moderate Buy."

Callan Family Office LLC boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 316.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,199 shares of the medical research company's stock after purchasing an additional 27,509 shares during the quarter. Callan Family Office LLC's holdings in Edwards Lifesciences were worth $2,831,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of EW. Brighton Jones LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $266,000. Farther Finance Advisors LLC increased its holdings in Edwards Lifesciences by 390.7% during the 1st quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company's stock worth $633,000 after purchasing an additional 7,013 shares during the last quarter. Pallas Capital Advisors LLC purchased a new stake in Edwards Lifesciences during the 1st quarter worth approximately $222,000. Wealthcare Advisory Partners LLC increased its holdings in shares of Edwards Lifesciences by 5.8% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 7,769 shares of the medical research company's stock valued at $563,000 after acquiring an additional 429 shares during the last quarter. Finally, Compagnie Lombard Odier SCmA bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $87,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 1.6%

NYSE:EW opened at $74.02 on Friday. Edwards Lifesciences Corporation has a 12-month low of $64.89 and a 12-month high of $83.00. The firm has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a P/E/G ratio of 3.55 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The business has a 50 day simple moving average of $78.09 and a 200 day simple moving average of $76.13.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the firm posted $0.70 EPS. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on EW. Evercore ISI set a $88.00 price target on Edwards Lifesciences and gave the company an "outperform" rating in a report on Tuesday. Stifel Nicolaus set a $85.00 price target on Edwards Lifesciences and gave the company a "buy" rating in a report on Monday, September 22nd. Mizuho boosted their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Barclays boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, July 25th. Finally, Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $87.06.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.